These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29742330)

  • 1. Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop.
    Kane JM; Correll CU; Nierenberg AA; Caroff SN; Sajatovic M;
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29742330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation.
    Farber RH; Stull DE; Witherspoon B; Evans CJ; Yonan C; Bron M; Dhanda R; Jen E; Brien CO'
    J Patient Rep Outcomes; 2024 Jan; 8(1):2. PubMed ID: 38175450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
    Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine.
    Hauser RA; Barkay H; Wilhelm A; Wieman M; Savola JM; Gordon MF
    Parkinsonism Relat Disord; 2022 Apr; 97():47-51. PubMed ID: 35299070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia.
    Caroff SN; Leong SH; Roberts CB; Berkowitz RM; Campbell EC
    J Clin Psychopharmacol; 2020; 40(4):373-380. PubMed ID: 32639290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical management of tardive dyskinesia: Five steps to success.
    Citrome L
    J Neurol Sci; 2017 Dec; 383():199-204. PubMed ID: 29246613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact-Tardive Dyskinesia (Impact-TD) Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia.
    Jackson R; Brams MN; Carlozzi NE; Citrome L; Fritz NE; Hoberg AR; Isaacson SH; Kane JM; Kumar R
    J Clin Psychiatry; 2022 Nov; 84(1):. PubMed ID: 36449471
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study.
    Correll CU; Cutler AJ; Kane JM; McEvoy JP; Liang GS; O'Brien CF
    J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30695293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 29024264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care.
    McEvoy JP
    J Clin Psychiatry; 2020 Nov; 81(6):. PubMed ID: 33147658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of valbenazine on tardive dyskinesia in older and younger patients.
    Sajatovic M; Alexopoulos GS; Burke J; Farahmand K; Siegert S
    Int J Geriatr Psychiatry; 2020 Jan; 35(1):69-79. PubMed ID: 31617235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
    McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J
    J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive Dyskinesia.
    Correll CU; Citrome L; Singer C; Lindenmayer JP; Zinger C; Liang G; Dunayevich E; Marder SR
    J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):353-361. PubMed ID: 38767901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia.
    Caroff SN; Citrome L; Meyer J; Sajatovic M; Goldberg JF; Jain R; Lundt L; Lindenmayer JP; McEvoy JP; McIntyre RS; Tohen M; Ketter TA
    J Clin Psychiatry; 2020 Jan; 81(2):. PubMed ID: 31995677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
    Factor SA; Remington G; Comella CL; Correll CU; Burke J; Jimenez R; Liang GS; O'Brien CF
    J Clin Psychiatry; 2017; 78(9):1344-1350. PubMed ID: 29141124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Clinician's Tardive Inventory (CTI): A New Clinical Tool for Documenting and Rating Tardive Dyskinesia.
    Trosch RM; Comella CL; Caroff SN; Ondo WG; Shillington AC; LaChappelle BJ; Hauser RA; Correll CU; Friedman JH
    J Clin Psychiatry; 2024 Jan; 85(1):. PubMed ID: 38270545
    [No Abstract]   [Full Text] [Related]  

  • 20. Extract of Ginkgo biloba for Tardive Dyskinesia: Meta-analysis of Randomized Controlled Trials.
    Zheng W; Xiang YQ; Ng CH; Ungvari GS; Chiu HF; Xiang YT
    Pharmacopsychiatry; 2016 May; 49(3):107-11. PubMed ID: 26979525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.